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Hairy cell leukemia (HCL) is a chronic lymphoproliferative B-cell disorder where the
B-RAF V600E mutation has been recently detected, as reported for solid neoplasias
but not for other B-cell lymphomas. The digital droplet PCR (dd-PCR) is a molecular
technique that, without standard references, is able to accurately quantitate DNA
mutations. ddPCR could be an useful instrument for the detection of the B-RAF V600E
mutation in HCL, where the minimal residual disease monitoring is fundamental for
planning a patients-targeted treatment in the era of new anti-CD20 and anti-RAF
compounds. This retrospective study enrolled 47 patients observed at the Hematology
Unit of the University of Pisa, Italy, from January 2005 to January 2014: 27 patients were
affected by “classic” HCL, two by the variant HCL (vHCL), and 18 by splenic marginal
zone lymphoma (SMZL). The aim of the study was to compare dd-PCR to “classic”
quantitative PCR (QT-PCR) in terms of sensitivity and specificity and to demonstrate
its possible use in HCL. Results showed that: (1) the sensitivity of dd-PCR is about
half a logarithm superior to QT-PCR (5 × 10−5 vs. 2.5 × 10−4), (2) the specificity of
the dd-PCR is comparable to QT-PCR (no patient with marginal splenic lymphoma or
HCL variant resulted mutated), (3) its high sensitivity would allow to use dd-PCR in the
monitoring of MRD. At the end of treatment, among patients in complete remission,
33% were still MRD-positive by dd-PCR versus 28% by QT-PCR versus 11% by the
evaluation of the B-cell clonality, after 12 months, dd-PCR was comparable to QT-PCR
and both detected the B-RAF mutation in 15% of cases defined as MRD-negative by
IgH rearrangement. Moreover, (4) the feasibility and the costs of dd-PCR are comparable
to those of QT-PCR. In conclusion, our study supports the introduction of dd-PCR in the
scenario of HCL, also during the follow-up.
Keywords: B-RAF, V600E, hairy cell leukemia, digital droplet PCR, immunoglobulins rearrangement, minimal
residual disease
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INTRODUCTION
B-RAF, located on the long arm of the chromosome 7 (Kamiyama
et al., 1993), is one of the three RAF genes (A-RAF, B-RAF, and
C-RAF) whose activation by their respective ligands (i.e., TGF-
alpha and EGF) induces the activation of several downstream
targets, such as ERK1/2, AP1, and NFAT, with the consequent
pro-proliferative and anti-apoptotic effect (Chong et al., 2003;
Flockhart et al., 2009; Grimaldi et al., 2015).
The B-RAF gene presents three fundamental domains: (1)
CR1, the amino-terminal portion, cysteine-enriched, where B-
RAF interacts with RAS; (2) CR2, with regulatory activity; (3)
CR3, the carboxy-terminal domain, with serine-threonine kinase
activity. The V600E mutation in exon 15 involves the CR3
domain, leading a constitutive activation of the B-RAF signal,
with the consequent uncontrolled proliferative signal (Lyons
et al., 2001).
This aberrant kinase activity is also sustained by the
overexpression of some non-coding miRNA, such as miR-221
and miR-222, whose expression in HCL is strictly related to the
B-RAF mutation (Ahmadzadeh et al., 2014).
In the recent years, mutations of B-RAF, especially the
V600E, have been reported in different types of cancer (Davies
et al., 2002): in the 50% of melanomas (DePeralta and Boland,
2015; El-Gamal et al., 2016) and papillary thyroid carcinomas
(Jiang et al., 2016), in about 10% of colon (Tie and Desai,
2015) and ovarian cancers (Pakneshan et al., 2013), and in rare
cases (1−3%) of non-small cell lung cancer (Caparica et al.,
2016).
In the 2011, for the first time, it has been reported
that the substitution of the adenine with a thymine at the
position 1799, causing the change of a valine with a glutamic
acid (the V600E mutation), characterizes 100% of the HCL,
allowing distinguishing this histotype from other indolent B-cell
lymphomas (Tiacci et al., 2011).
Later, other groups confirmed those results: Arcaini
et al. (2012) assessed by allele-specific polymerase chain
reaction (ASO-PCR) 240 cases affected by mature B-cell
lymphoproliferative disorders, including 62 cases of HCL: the
B-RAFV600E mutation was detected in all HCL cases, thus
confirming that this marker is useful for differentiating HCL
from other mimicking lymphomas. Indeed, no patients
affected by marginal zone lymphoma or Waldenstrom
macroglobulinemia carried the B-RAF mutation. Also the
variant HCL (v-HCL) was unmutated (Arcaini et al., 2012).
More recently, mutations of MAP2K1 have been reported in
unmutated HCL, in addition to the “classical” forms carrying the
VH4-34 rearrangement (Mason et al., 2016).
Hairy cell leukemia is a rare B-cell, chronic and indolent
lymphoproliferative disease characterized by the bone marrow
and spleen/lymph nodes infiltration by pathological CD20+,
Abbreviation: ARMS PCR, Amplification Refractory Mutation System PCR; ASO-
PCR, allele-specific-oligonucleotide PCR; CR, complete remission; dd-PCR, digital
droplet PCR; HCL, hairy cell leukemia; IgH, heavy chain of immunoglobulins;
miRNA, micro RNA; MRD, minimal residual disease; PR, partial response; QT-
PCR, quantitative real-time PCR; SMZL, splenic marginal zone lymphoma; v-HCL,
hairy cell leukemia variant; WHO, world health organization.
CD103+, CD25+, CD11c, sIg+, CD5-, CD23-, CD10-
lymphocytes (Getta et al., 2015).
Purine analogs (cladibrine, pentostatine) have been reported
to induce more than 90% of complete hematological responses
(CRs), with 10−40% of relapses or progressions at 16 years
(Else et al., 2015; Ravandi, 2015). When MRD is detected by
immunohistochemistry, the risk of relapse is significantly higher,
thus sustaining the predictive role of the MRD assessment also in
this disease (Tallman, 2011).
Nevertheless, in the era of molecular biology and new
generation sequencing the immunohistochemistry is not the best
technique for the MRD evaluation, especially considering that
after the introduction of the anti-B cell therapies (anti-CD20,
anti-CD22 antibodies) and of the anti-RAF compounds (such as
vemurafenib), the possibility of detecting the persistent disease
even in a phase of clinical remission is fundamental to design
more complex therapeutic strategies that would include “pre-
emptive” and/or targeted treatments (Kreitman, 2013).
Today, among the available different molecular techniques,
a clear statement on which one would be the best one is still
lacking. In 2006, 84 samples from 10 HCL patients were tested
for MRD using both flow cytometry and ASO-PCR for the heavy
chain immunoglobulin (IgH) rearrangement: the ASO-PCR, with
a sensitivity of 1 × 10−6, confirmed the results obtained with
the flow cytometry and allowed detecting MRD in 91% of
cases already defined as CR by the morphological analysis and
flow cytometry, with a significant correlation with the clinical
outcome (Arons et al., 2006).
In 2008, our group treated 27 HCL patients with rituximab
after cladribrine; overall response rate after cladribrine was 89%,
with 26% of CRs; after rituximab, CR rate increased up to
89%; concomitantly, a progressive increment in the number of
molecular remissions was observed, with MRD-negative cases
passing from 40% after cladibrine to 70% after rituximab. The 5-
year PFS was 83%, and it was not influenced by age, bone marrow
infiltration at diagnosis or quality of response to cladribine, but
only by the molecular status after rituximab: 30% of cases still
MRD-positive after rituximab remained disease-free vs. 100% of
those reaching MRD-negativity after rituximab (Cervetti et al.,
2008).
In 2013, Burotto et al. showed that bendamustine offered 100%
of overall responses with 30% of CRs, and also in this setting
MRD predicted the maintenance of response (Burotto et al.,
2013).
Because all HCL cases show the B-cell clonality (90% exhibit
VH mutation), the IgH evaluation has been long-term considered
the technique of choice for the MRD assessment (Miranda et al.,
1999; Sausville et al., 2003). Nevertheless, after discovery of the
B-RAF mutation, the molecular techniques able to identify this
mutation appeared as new more promising tools. Among them,
the dd-PCR would be suitable for detecting the B-RAF V600E
mutation at diagnosis and during follow-up of HCL patients.
Firstly used by Vogelstein and Kinzler (1999) for detecting
RAS mutations, the high sensitivity and specificity of the dd-
PCR, represents a very promising molecular approach: in acute
myeloid leukemia, DNMT3A o IDH1/2 mutation detected by dd-
PCR were comparable to those obtained by the conventional
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Sanger sequencing (Brambati et al., 2016). In acute lymphoblastic
leukemia, mantle cell lymphoma and multiple myeloma, dd-
PCR has been employed in the MRD monitoring: results were
comparable to those produced by the conventional ASO-PCR
in 94% of cases. In addition, in the 27% of cases reported as
“positive not quantifiable” by ASO-PCR, dd-PCR allowed their
quantification (Drandi et al., 2015). Also in chronic myeloid
leukemia dd-PCR showed a higher sensitivity with respect to
the conventional PCR (Zagaria et al., 2015); in the ISAV study,
dd-PCR, able to detect one BCR-ABL1-positive cell out of 10−7,
was validated for its predictive role in terms of relapses after
imatinib discontinuation in patients with undetectable transcript
by QT-PCR. dd-PCR showed a significant negative predictive
value, superimposable to that of the conventional PCR (Mori
et al., 2015). Finally, our group reported that dd-PCR represents
a good technique for assessing the JAK2 V618F mutation in
Philadelphia-negative chronic myeloproliferative neoplasias. In
this setting, the possibility of detecting and quantitating the
mutation at the same time makes dd-PCR a very competitive
method, also in terms of costs (Fontanelli et al., 2015).
The purpose of the present study was to evaluate the
introduction of dd-PCR as a molecular approach for the
B-RAF V600E detection and its comparison with the QT-
PCR and IgH rearrangement, at diagnosis and during the
follow-up of patients affected by HCL. The advantage of
adopting a specific and sensitive technique in HCL is obvious:
the identification of the B-RAF mutation is fundamental for
deciding if, how and when starting a further “patient-tailored”
strategy, including the possibility of retreating still MRD-positive
patients with the anti-CD20 antibodies as “pre-emptive” therapy
or using vemurafenib or rituximab-bendamustine in relapsed
cases.
MATERIALS AND METHODS
Patients
This retrospective study enrolled 47 patients observed at the
Hematology Unit of the University of Pisa, Italy, from January
2005 to January 2014.
Clinical characteristics are detailed in Tables 1 and 2: 27
patients were affected by the “classic” HCL, two by the vHCL
(Table 1), and 18 by SMZL (Table 2). These latest patients were
used as controls to evaluate the specificity of the methods, because
the B-RAF V600E mutation has never been detected in this
indolent lymphoma subtype.
Diagnosis of non-Hodgkin’s lymphoma was made on the
basis of peripheral blood and bone marrow morphology,
immunophenotype (sIg+, CD5−, CD20+, CD5/CD19−,
CD25+, CD11c+, CD103+, CD10−, CD23−), clinical
chemistry, imaging (chest X-ray or CT, ultrasonography of
abdomen, neck, axillae, groins) or histology of suspected
masses or of the spleen after surgery, according to the WHO
classification 2008 (Campo et al., 2011).
On the paraffin-included samples also DBA-44 antibody
has been employed in addition to the morphological analysis
(Salomon-Nguyen et al., 1996).
The study was conducted according to the Helsinki
declaration rules; all patients signed procedure AOUP n.
1801/T.01 February 2015 the informed consent in order to
participate to the study and genomic DNA was collected and
stored at the Hematology Unit of Pisa until its analysis. The only
two inclusion criteria were: (1) the presence of good quality of
DNA, and (2) the availability of clinical information (at diagnosis
and during the follow-up).
It has to be noted that all patients included in the present
study have been previously monitored by the qualitative PCR
for the IgH rearrangement at diagnosis, after 3 months of
treatment, and by 40 days from the end of therapy as routinary
work-up.
Treatment
Indication for treatment was represented by a neutrophil count
<1 × 109/L, hemoglobin <10 g/dL, platelets <100×109/L,
massive lymphocytosis, symptomatic splenomegaly, more
TABLE 1 | Clinical features of the enrolled HCL patients.
HCL patients (29) n◦ %
Age Median (y) 58
Range (y) 35−78
Sex Male
Female
21
8
72
28
Splenomegaly Yes
Mild
Large
27
22
5
93
81.5
18.5
Lymph nodes enlargement No
Yes
19
10
65.5
34.5
Bone marrow biopsy HCL infiltration
Range
Median
20 100
30−90
64.21
Cytopenias Hb < 11 g/dL
N < 1 × 109/L
PLT < 100 × 109/L
6
12
18
20.6
41.4
62
TABLE 2 | Clinical features of the enrolled SMZL patients.
SMZL patients (18) n◦ %
Age Median (y)
66.8
Range (y)
56−78
Sex Male
Female
13
5
72
28
Splenomegaly Yes
Mild
Large
17
9
8
94.4
53
47
Lymph nodes enlargement No
Yes
17
1
94.5
5.5
Bone marrow biopsy HCL
infiltration
Range
Median
19 66.7
30−60
50
Cytopenias Hb< 11 g/dL
N< 1× 109/L
PLT< 100× 109/L
8
3
10
44.4
16.6
55.5
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than three enlarged nodes, or a history of repeated
infections.
Patients affected by SMZL received oral cyclophosphamide
100 mg/day for 2 weeks every month in combination with
rituximab 375 mg/m2 i.v. the day 8, for total six cycles, as reported
by our group (Cervetti et al., 2016).
Among HCL patients, 26 received rituximab in combination
with cladribine, and three alpha-interferon, at dose of three MUI
three times a week.
Cladribine was infused at 0.12 mg/kg per 5 days/month
for 6 months in patients aged <65 years or at 0.14 mg/Kg
each week for total six consecutive weeks in older
subjects.
Clinical Response Assessment
Complete remission was defined as the absence of HCL
lymphocytes in peripheral blood and in bone marrow after
microscopy observation, no palpable splenomegaly or lymph
nodes >2 cm, neutrophils ≥1.5 × 109/L, platelets ≥100 × 109/L
and hemoglobin ≥11 g/dL.
Partial response required ≥50% reduction in the circulating
HCL cells or spleen enlargement, and at least a ≥50%
improvement of the peripheral blood values over baseline.
Progressive disease (PD) required appearance of
eventual pathological lymph nodes, a ≥ 50% increase
in the spleen size or a ≥50% increase in circulating HCL
cells.
Stable disease was defined as lack of CR, PR, or PD.
DNA Extraction
DNA extraction from 12 mL of bone marrow anti-coagulated
with EDTA was performed using the automatic apparatus
BioRobot EZ1, the EZ1 DNA Blood Card, and the EZ1 DNA
Blood 350 l L Kit (Qiagen R©, Valencia, CA, USA).
The extracted DNA was maintained at 2–8◦C and quantitated
using the Thermo Scientific NanoDrop 2000 spectrophotometer
(Thermo Fisher Scientific R©, Wilmington, DE, USA).
Qualitative PCR for the IgH
Rearrangement
Qualitative PCR for IgH rearrangement has been performed
by fluorescent PCR, as previously described by our group
(Galimberti et al., 1999; Cervetti et al., 2004).
B-RAF V600E Mutation and Real-Time
PCR (ARMS PCR)
Molecular analysis of the B-RAF V600E mutation was performed
by real-time PCR (QT-PCR) using the Amplification Refractory
Mutation System (ARMS) technology, which is based on
the discrimination by Taq polymerase between matched and
mismatched primers specifically designed for amplifying the
mutated target DNA. The QT-PCR was performed on the ABI
Prism 7900 HT apparatus (Applied Biosystems R©, Foster City,
CA, USA) with the qBiomarker Somatic Mutation PCR Assay
(BRAF_476 #SMPH001828AR, Qiagen R©, Valencia, CA, USA). All
samples and controls were amplified and analyzed in duplicate,
according to the manufacturer’s instructions.
The data analysis was based on the “11Ct” method: the
amount of mutant DNA was calculated by the formula: “1Ct
sample” = Ct of mutated allele – Ct of wild-type copy number;
“1Ct healthy donor” = Ct of mutated allele – Ct of wild-type
copy number.
“11Ct”=1Ct sample –1Ct healthy donor. A mutation call
can be made when11Ct> 4; when11Ct is< 3 the sample was
considered as wild-type; when 11Ct was between 3 and 4, the
specimen resulted borderline.
Moreover, samples were defined as unmutated if Ct of the
mutated allele was>37 (total cycles of amplification= 40).
For the relative quantitation, at each time point 2−11CT in
respect of sample at diagnosis was calculated.
B-RAF V600E Mutation and dd-PCR
B-RAF V600E mutation was detected by using the specific
dd-PCR BioRad assays (#10031249 assay for wild-type and
#10031246 assay for mutated amplifications). dd-PCR was
performed using the QX100 platform (BioRad R©, Hercules, CA,
USA), consisting of two instruments: the droplet generator and
the droplet reader. The droplet generator divides the sample by
creating about 20,000 partitions (droplets). The droplets are then
transferred into PCR plates and, at the end of the amplification
cycles, placed into the droplet reader, where each droplet is read
as mutated or wild-type by issuing specific fluorescence signals
(FAM for the mutation and Hex for the wild-type). These signals,
after being counted, are redistributed according to the Poisson’s
algorithm.
VH Sequencing
In order to test if B-RAF-unmutated cases could present the
VH4-34 rearrangement, three samples were sequenced on an ABI
PRISM 3100 (Applied Biosystems R©, Foster City, CA, USA) using
the Sequencing Analysis Software v 5.1. All samples were analyzed
by monoplex PCR method using six different consensus primers
corresponding to the Leader VH regions (Campbell et al., 1992)
in combination with a JH consensus primer. Clonal products
were purified by Wizard SV R© Gel and PCR Clean-Up System
(Promega R©, Madison, WI, USA) and sequenced using BigDye
Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems R©,
Foster City, CA, USA).
The sequences were analyzed by IgBlast Network
(http://www.ncbi.nlm.nih.gov/igblast/) and IMGT Information
System R©(http://www.imgt.org/IMGT_vquest/) in order
to identify and quantify the IGH germline homology of
clones.
Statistical Analysis
Median and mean values of mutational burden at each
time point were measured and then compared with
the t-test. Differences were considered significant at
p < 0.05. Analyses were performed using the SPSS 22.0
software (IBM SPSS Statistics 20; IBM Corporation, NY,
USA).
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RESULTS
Sensitivity of the Employed Molecular
Techniques
The IgH rearrangement evaluation by fluorescent PCR has been
adopted in our center from many years as a simple, rapid and
cheap method for the evaluation of the B-cell clonality in all B-cell
lymphoproliferative diseases. In our hand, the sensitivity of this
technique ranges from 1 × 10−2 to 1 × 10−3, according to the
position of the clonal peak inside the Gaussian curve (Cervetti
et al., 2004).
Differently from this assay, QT-PCR and dd-PCR, both able
to assess the B-RAF V600E mutation, allow us giving both a
qualitative and quantitative estimate of the mutational burden.
While in literature data concerning the sensitivity of the QT-
PCR and the dd-PCR in HCL are few, analytic sensitivity tests
have been performed at the start of the study, diluting a DNA
from a HCL patient with 5% of B-RAF mutation in a pool of 5
wild-type DNAs (extracted from patients without hematological
diseases during orthopedic surgery) in a half-logarithmic scale,
from 1× 10 to 1× 10−4 dilution.
The QT-PCR allowed detecting the B-RAF V600E mutation
up to 5x10−3; considering that undiluted DNA corresponded to a
mutational burden of 5%, the sensitivity of QT-PCR thus resulted
of 2.5× 10−4 (Figure 1A).
On the other hand, dd-PCR still detected mutation at
1 × 10−3, that corresponds to a sensitivity of 5 × 10−5; thus,
dd-PCR showed a sensitivity of more than half a log higher than
that offered by QT-PCR (Figure 1B).
Assessment of the IgH Clonality on
Diagnostic Samples
In order to demonstrate a clonal lymphocytic infiltration in all
samples, we performed flow cytometry with assessment of κ and
λ clonality and then amplified the IgH rearrangement, either in
patients affected by HCL or in those with SMZL.
As expected, all the 18 cases with SMZL, all 27 patients affected
by “classic” HCL and the two cases with v-HCL showed an
evident IgH clonality.
QT-PCR and dd-PCR for the B-RAF
V600E Mutation on Diagnostic Samples
First of all, we started to test the presence of the B-RAF V600E
mutation; when we used the QT-PCR, all 18 SMZL cases resulted
unmutated, as expected. The same negative results were obtained
in the two patients affected by the v-HCL.
In the remaining 27 “typical” HCL cases, the B-RAF mutation
was found in 24 patients (88.8%).
Thus, we sequenced the VH rearrangement in the three
unmutated samples; in one of them the rearrangement resulted
VH4-34, thus confirming data from the literature where this
kind of VH rearrangement is characterized by the absence of the
B-RAF V600E mutation in “classic” HCL (Schnittger et al., 2012).
Thus, after discharging from the computation the two v-HCL
patients and the case with the VH4-34 rearrangement, QT-PCR
was able to identify the B-RAF V600E mutation in 24/26 patients
(92.3%).
Then, the same DNA were used for the dd-PCR runs; even
with this technique, the two cases with v-HCL and the VH4-
34 patient resulted unmutated, so confirming the same rate of
detectability already obtained by the QT-PCR (92.3%).
Clinical Outcome and Follow-Up
After the demonstration that the B-RAF mutation was a specific
marker of HCL also in our series, we employed either QT-PCR
or dd-PCR for the assessment of MRD in the 24 cases with the
molecular marker at diagnosis.
After 3 months of treatment, 9 patients achieved the CR
(37.5%), 14 (58.3%) the PR, and one (4.2%) was not responding
to treatment (overall response rate= 95.8%).
At the second time point (the end of treatment), all cases
responded, 17 patients with CR (70.8%) and 7 with PR (29.2%).
At the 12th month, 9 patients were re-assessed: 7 were in CR
(4 have previously been in PR), and 2 progressed (from PR).
The IgH and the B-RAF V600E Mutation
as Markers of MRD
At the first evaluation (third month of treatment), nine patients
achieved the CR, 14 a PR, and one was not responsive to
treatment.
A clonal IgH rearrangement was still detectable in 18 out of
the 24 tested cases (75%). In particular, the B-cell clonality was
still present in 13 out of the 14 cases in PR (93%), in the patient
with stable disease, and in 4 of the 9 cases in CR (44.4%).
When QT-PCR was performed, the B-RAF V600E mutation
was still detectable in 16 out of the 24 tested cases (66.6%). In
particular, B-RAF mutation was still present in 12 out of the 14
cases in PR (85.7%), in the patient with stable disease, and in 3 of
the 9 cases in CR (33.3%).
Then, dd-PCR was done: the B-RAF mutation was still
detectable in 18 out of the 24 tested cases (75%). In particular, the
mutation was still present in 11 out of the 14 cases in PR (78.6%),
in the patient with stable disease, and in 6 of the 9 cases in CR
(66.6%).
At the second time point (the end of treatment), 17 patients
were in CR and 7 in PR.
A clonal IgH rearrangement was still detectable in 10 out of
the 24 tested cases (41.7%). In particular, the B-cell clonality was
still present in all cases in PR (100%), and in 3 of the 17 cases in
CR (17.6%).
When QT-PCR was performed, the B-RAF V600E mutation
was still detectable in 11 out of the 24 tested cases (45.8%). In
particular, mutation was still present in 5 cases in PR (71.4%),
and in 6 of the 17 cases in CR (35.3%).
Then, dd-PCR was also performed: the B-RAF mutation was
still detectable in 13 out of the 24 tested cases (54%). In particular,
mutation was still present in 5 of the 7 cases in PR (71.4%), and
in 8 of the 17 cases in CR (47%).
At the month +12, 9 cases B-RAF-mutated at the end of
treatment have been re-assessed: 7 were in CR (4 have previously
been in PR), and 2 progressed from a PR.
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FIGURE 1 | Diluting a DNA from a HCL patient with 5% of B-RAF mutation in a pool of five wild-type DNAs in a half-logarithmic scale, from the 1 × 10
to the 1 × 10−4 dilution. (A) In the QT-PCR the copy number Ct remained constant (green), while the mutated Ct increased (blue). In orange the trend of the 11Ct
which is reduced up to 1.69. The 1 × 10−3 dilution should be considered negative, because Ct was >37 and 11Ct < 4.0. (See Materials and Methods) The
∗ indicates the last dilution point that can be accepted (1 × 10−3). (B) In the dd-PCR the copy number concentration remained constant (green), while the mutated
concentration reduced (blue). In orange the trend of the fractional abundance (%) which reduced up to 0.005. The ∗ indicates the last dilution point that can be
accepted (1 × 10−3). Ct. cycle threshold; MUT, mutated; WT, wild-type
Of the seven patients in CR, three still resulted MRD-positive
by the IgH rearrangement (42.8%), and four still retained the
B-RAF mutation (57.1%), either by QT-PCR or by dd-PCR (see
Table 3). It is interestingly to observe that, even if still mutated,
patients in CR reduced the mutational burden of more than one
log in respect of the mutational burden measured at the end
of therapy. In particular, the four cases coming from PR to CR
significantly reduced the mutational burden, from a median value
of 0.40 to 0.05%.
Two patients progressed: in the first case the mutational
burden increased from 2.12 to 2.45%, and in the second one from
0.01 to 1.36% (see Figure 2).
dd-PCR and Quantitative Assessment
In order to verify if the quantitation of the B-RAF V600E
mutation by dd-PCR could significantly correlate with the clinical
status (thus representing a valid tool for MRD evaluation),
we performed the t-test among the three groups: (1) cases at
diagnosis; (2) cases in PR; (3) cases in CR.
At diagnosis, the mean ± standard deviation of the B-RAF
V600E mutation was 6.82% ± 3.31%; in the group of patients in
PR, it was 0.88%± 1.18%, and in patients who achieved the CR it
amounted to 0.047%± 0.13%.
After statistical analysis, differences among three groups were
significant: diagnosis vs PR: p= 0.03; diagnosis vs. CR: p= 0.002;
PR vs. CR: p= 0.016 (Figure 3).
DISCUSSION
In the more recent years, the “targeted” therapy has became a
reality even in hematology: in the chronic myeloid leukemia,
the management of patient and the eventual switch to a second
or third tyrosine-kinase inhibitor is leaded by the assessment
of the BCR-ABL1/ABL1 ratio and by the demonstration of
mutations in the tyrosine domain of ABL1, as defined by
the European Leukemia Network guidelines (Baccarani et al.,
2013).
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TABLE 3 | Comparison among qualitative PCR for IgH rearrangement,
QT-PCR for B-RAF V600E mutation, and dd-PCR.
Percentage of patients with a molecular marker
IgH (%) QT-PCR (%) dd-PCR (%)
Diagnosis 100 96.4 96.4
3 months (total) 64 60 72
SD 100 100 100
PR 93 85.7 85.7
CR 30 20 50
End of treatment (total) 36 48 52
PR 100 87.5 87.5
CR 11 27.7 33.3
+ 12 months
CR 42.8 57.1 57.1
Percentages of cases having a molecular marker are reported at diagnosis, after
3 months of treatment, and at the end of therapy.
In mantle cell lymphoma, the Nordic group clearly
demonstrated the predictive role of the MRD assessed by
ASO-PCR, either in the setting of the conventional therapy or of
the high-dose treatment (Pott et al., 2010).
In the follicular lymphoma, it has been reported that the
PET-negativity in association with the molecular MRD-negativity
is predictive of longer PFS (Luminari et al., 2016), with the
possibility of avoiding the rituximab maintenance for patients at
low risk of progression but, on the other hand, the necessity of
a further consolidation in cases still PET-positive and/or MRD-
positive (FIL FOLL12 trial is now being performed to confirm
this hypothesis - EUDRACT NUMBER: 2012-003170-60).
In the meantime, the “pre-emptive” therapy (4 weekly doses
of rituximab in patients still molecularly MRD-positive) has been
shown to be efficacious to avoid relapses in follicular lymphoma
(Ferrero et al., 2013), and probably this strategy could be useful
in other indolent B-cell malignancies, including HCL.
With these premises, the idea of establishing already at
diagnosis a patient-specific therapeutic project is now a reality;
nevertheless, it is obvious that this approach needs a disease-
specific molecular marker.
As occurs for BCR-ABL1 in the chronic myeloid leukemia,
the IgH clonality is a well-recognized universal marker for B-cell
FIGURE 2 | Comparison of MRD in three HCL cases by qualitative PCR for IgH rearrangement, QT-PCR, and dd-PCR. (A) Patient achieved the CR after
3 months and maintained it at the end of treatment. QT-PCR was negative already at the first point when dd-PCR and IgH rearrangement were positive. The
mutational burden measured by dd-PCR reduced from 4.87 at diagnosis to 2 at 3 months and became negative at the end of treatment. IgH rearrangement also
became negative at the end of therapy. (B) Patient achieved the PR after 3 months and the CR at the end of treatment. The IgH rearrangement remained clonal also
when CR was achieved. The mutational burden measured by dd-PCR reduced from 4 at diagnosis to 2 at 3 months when response was partial. At this time point,
QT-PCR was already negative. (C) Patient achieved the PR after 3 months but progressed at the end of treatment. IgH was positive both at 3 months and at the end
of therapy. QT-PCR mutational burden reduced at the first time point and increased from 0.1 to 9.15 at the sixth month. The mutational burden measured by
dd-PCR decreased from 1 at diagnosis to 0.01 at 3 months and increased up to 1.4 at the end of treatment.
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FIGURE 3 | T-test for dd-PCR fractional abundance and status of
disease. Diagnosis (red box) vs. PR (violet box): p = 0.03; diagnosis (red box)
vs. CR (green box): p = 0.002; PR (violet box) vs. CR (green box): p = 0.016
lymphomas, but the qualitative tests are not very sensitive and
the quantitative ones need the design of patient-specific primers,
with consequent lot of job and costs, and the possibility of
missing an eventual emerging new clone carrying a different VH
rearrangement (van der Velden et al., 2003; Della Starza et al.,
2014).
In the specific setting of HCL, the discovery of the B-
RAF V600E mutation as specific molecular marker opened the
possibility of using this mutation both at diagnosis and during
the follow-up for the MRD assessment.
In the present study, we applied to 18 cases affected by SMZL
and 29 cases with HCL two different molecular techniques to
detect the B-RAF V600E mutation: the QT-PCR and the dd-PCR.
Both methods allowed us identifying the presence of the B-
RAF mutation and the quantitative estimation of the mutational
burden, with an obvious advantage with respect of the qualitative
IgH assessment, on the basis of results coming from the follicular
lymphoma (Galimberti et al., 2014), that the quantitative MRD
evaluation would be more predictive than the qualitative one.
Moreover, no data about dd-PCR in HCL have been previously
reported in literature.
Schnittger et al. (2012) reported a valid QT-PCR method
for identifying and quantitating the B-RAF V600E mutation.
They applied this technique to 117 HCL cases and 102 control
samples (patients affected by myeloid or other B and T-lymphoid
malignancies), demonstrating that the QT-PCR, with sensitivity
between 10−4 and 10−5, was able to detect the B-RAF mutation in
98.3% of tested cases. All 16 v-HCL included in the study resulted
unmutated, analogously to the two cases with a “classical” HCL,
but with the VH4-34 rearrangement. In the same paper, 16
patients were followed during treatment: in patients achieving a
stable CR the mutational burden decreased up to 2 logs, whereas
in the relapsed case it did not decrease after treatment. The
authors concluded that the QT-PCR for B-RAF V600E mutation
represented a valid approach, either at diagnosis or during the
follow-up of HCL patients (Schnittger et al., 2012).
Our present study went to the same conclusion: the sensitivity
of our QT-PCR was comparable to that of the German group
(2.5 × 10−4); at diagnosis, our method detected the B-RAF
mutation in 92.3% of cases. This percentage is 6% lower than that
reported by Schnittger et al. (2012): we found in our series the
same two unexplainable unmutated cases (no v-HCL, no VH4-
34 rearrangement) of the German group, but in a smaller total
number of cases.
Analogously to that already reported in the German paper, the
specificity of our QT-PCR was optimal, because no cases with
v-HCL or SMZL resulted B-RAF mutated.
Nevertheless, the real innovation of our study was the
introduction of the innovative dd-PCR: in respect of
“conventional” PCRs, dd-PCR has got the great advantage
of avoiding the plasmidic reference curve, while it allows an
absolute quantitation of the mutational burden, as occurs for the
QT-PCR. Moreover, its sensitivity resulted optimal (5x10−5),
as previously shown in our experience on myeloid neoplasias
(Fontanelli et al., 2015).
As above reported, dd-PCR is entering now in the diagnosis
and follow-up of several hematological neoplasias (Camus et al.,
2016; Della Starza et al., 2016; Ommen, 2016). Thus, we
considered that also the HCL could be a good field where to apply
the dd-PCR.
In the present experience, dd-PCR resulted comparable to the
other PCR techniques: at diagnosis, it allowed to identify the B-
RAF mutation in 92.3% of cases with respect to the 100% of
the IgH rearrangement. Nevertheless, as discussed above, IgH is
not a specific marker for HCL, and so it cannot be used in the
differential diagnosis from other indolent lymphomas. On the
contrary, dd-PCR is a sensitive and specific technique, useful also
in the diagnostic phase, where usually molecular biology is used
in association with the flow cytometry.
About the possibility of using dd-PCR for MRD assessment, at
the first time point, in the subgroup of CR patients (where MRD is
relevant), dd-PCR was able to classify as still MRD-positive two
cases already defined as MRD-negative by qualitative PCR and
three of those resulted unmutated after QT-PCR. Effectively, dd-
PCR missed the molecular marker in two cases showing the IgH
clonality; nevertheless, these patients were in PR, condition where
the MRD is less significant.
Moreover, the advantage in terms of MRD detection offered
by the dd-PCR was present also at the second time points: at
the end of treatment, dd-PCR identified as MRD-positive two
of cases in CR resulting MRD-negative by the QT-PCR and five
cases already defined as negative by the qualitative PCR for the
IgH rearrangement.
Moreover, dd-PCR is interesting also from a technical point
of view, because (1) it does not need a plasmidic reference curve,
with the clear advantage of a minor contamination risk, and (2) it
is easier to perform than the ASO-PCR, because it does not need
the design of patient-specific primers; (3) the costs of dd-PCR are
superimposable to those of QT-PCR, as we already showed in our
previous experience in myeloproliferative neoplasias (Fontanelli
et al., 2015).
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Finally, as already reported by the German group for the
QT-PCR, in our study also the dd-PCR well correlated with
the clinical outcome: patients achieving PR or CR showed a
great precocious reduction of the mutational burden, opposite
to cases who progressed (where the B-RAF mutational burden
progressively increased). The achievement of the CR was
characterized by a reduction of the mutational burden of more
than one log, as already reported even in the German paper
(Schnittger et al., 2012).
Moreover, our statistical analysis showed that the mean of
mutational burden significantly correlated with the clinical status.
CONCLUSION
Our study supports the introduction of dd-PCR in the molecular
assessment of HCL patients, both at diagnosis and during the
follow-up. It could be clinically relevant considering that in the
next future the availability of the new anti-CD20 monoclonal
antibodies and of further anti-B-RAF compounds could be used
on the basis of the “dynamic” molecular marker (alias mutational
burden) monitoring.
AUTHOR CONTRIBUTIONS
All authors participated to the conception of the study.
FG, MP, EC, SG, SS, GE, MM, MDR, IP performed
PCR assays. SG, FG, LI, GC, NC, MR, GC, enrolled
patients, performed flow cytometry analysis, treatment,
and clinical follow-up. SG and FG performed statistical
analyses. All authors approved the final version of the
manuscript.
REFERENCES
Ahmadzadeh, A., Shahrabi, S., Jaseb, K., Norozi, F., Shahjahani, M., Vosoughi, T.,
et al. (2014). BRAF mutation in hairy cell leukemia. Oncol. Rev. 8, 253. doi:
10.4081/oncol.2014.253
Arcaini, L., Zibellini, S., Boveri, E., Riboni, R., Rattotti, S., Varettoni, M., et al.
(2012). The BRAF V600E mutation in hairy cell leukemia and other mature
B-cell neoplasms. Blood 119, 188–191. doi: 10.1182/blood-2011-08-368209
Arons, E., Margulies, I., Sorbara, L., Raffeld, M., Stetler-Stevenson, M., Pastan, I.,
et al. (2006). Minimal residual disease in hairy cell leukemia patients assessed by
clone-specific polymerase chain reaction. Clin. Cancer Res. 12, 2804–2811. doi:
10.1158/1078-0432.CCR-05-2315
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley,
J. F., et al. (2013). European LeukemiaNet recommendations for the
management of chronic myeloid leukemia: 2013. Blood 122, 872–884. doi:
10.1182/blood-2013-05-501569
Brambati, C., Galbiati, S., Xue, E., Toffalori, C., Crucitti, L., Greco, R., et al. (2016).
Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations
to improve early detection of acute myeloid leukemia relapse after allogeneic
hematopoietic stem cell transplantation. Haematologica 101:e157–e161. doi:
10.3324/haematol.2015.135467
Burotto, M., Stetler-Stevenson, M., Arons, E., Zhou, H., Wilson, W., and Kreitman,
R. J. (2013). Bendamustine and rituximab in relapsed and refractory hairy cell
leukemia. Clin. Cancer Res. 19, 6313–6321. doi: 10.1158/1078-0432.CCR-13-
1848
Campbell, M. J., Zelenetz, A. D., Levy, S., and Levy, R. (1992). Use of family
specific leader region primers for PCR amplification of human heavy chain
variable region gene repertoire. Mol. Immunol. 29, 193–203. doi: 10.1016/0161-
5890(92)90100-C PMID: 1542297
Campo, E., Swerdlow, S. H., Harris, N. L., Pileri, S., Stein, H., and Jaffe, E. S. (2011).
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving
concepts and practical applications. Blood 117, 5019–5032. doi: 10.1182/blood-
2011-01-293050
Camus, V., Sarafan-Vasseur, N., Bohers, E., Dubois, S., Mareschal, S., Bertrand, P.,
et al. (2016). Digital PCR for quantification of recurrent and potentially
actionable somatic mutations in circulating free DNA from patients with
diffuse large B-cell lymphoma. Leuk. Lymphoma 57, 2171–2179. doi:
10.3109/10428194.2016.1139703
Caparica, R., de Castro, G. Jr., Gil-Bazo, I., Caglevic, C., Calogero, R.,
Giallombardo, M., et al. (2016). BRAF mutations in non-small cell lung cancer:
has finally Janus opened the door? Crit. Rev. Oncol. Hematol. 101, 32–39. doi:
10.1016/j.critrevonc.2016.02.012
Cervetti, G., Galimberti, S., Andreazzoli, F., Fazzi, R., Cecconi, N., Caracciolo, F.,
et al. (2004). Rituximab as treatment for minimal residual disease in
hairy cell leukaemia. Eur. J. Haematol. 73, 412–417. doi: 10.1111/j.1600-
0609.2004.00325.x
Cervetti, G., Galimberti, S., Andreazzoli, F., Fazzi, R., Cecconi, N., Caracciolo, F.,
et al. (2008). Rituximab as treatment for minimal residual disease in hairy
cell leukaemia: extended follow-up. Br. J. Haematol. 143, 296–298. doi:
10.1111/j.1365-2141.2008.07333.x
Cervetti, G., Ghio, F., Cecconi, N., Morganti, R., Galimberti, S., and Petrini, M.
(2016). How to treat splenic marginal zone lymphoma (SMZL) in patients unfit
for surgery or more aggressive therapies: experience in 30 cases. J. Chemother.
25, 1–4. doi: 10.1080/1120009X.2015.1114222
Chong, H., Vikis, H. G., and Guan, K. L. (2003). Mechanisms of regulating the Raf
kinase family. Cell. Signal. 15, 463–469. doi: 10.1016/S0898-6568(02)00139-0
PMID: 12639709
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S. K., et al.
(2002). Mutations of the BRAF gene in human cancer. Nature 417, 949–954.
doi: 10.1038/nature00766
Della Starza, I., Cavalli, M., Del Giudice, I., Barbero, D., Mantoan, B.,
Genuardi, E., et al. (2014). Comparison of two real-time quantitative
polymerase chain reaction strategies for minimal residual disease evaluation
in lymphoproliferative disorders: correlation between immunoglobulin
gene mutation load and real-time quantitative polymerase chain reaction
performance. Hematol. Oncol. 32, 133–138. doi: 10.1002/hon.2095
Della Starza, I., Nunes, V., Cavalli, M., De Novi, L. A., Ilari, C., Apicella, V.,
et al. (2016). Comparative analysis between RQ-PCR and digital-droplet-PCR
of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal
residual disease in acute lymphoblastic leukaemia. Br. J. Haematol. 174, 541–
549. doi: 10.1002/hon.2095
DePeralta, D. K., and Boland, G. M. (2015). Melanoma: advances in targeted
therapy and molecular markers. Ann. Surg. Oncol. 22, 3451–3458. doi:
10.1245/s10434-015-4702-1
Drandi, D., Kubiczkova-Besse, L., Ferrero, S., Dani, N., Passera, R., Mantoan, B.,
et al. (2015). Minimal residual disease detection by droplet digital PCR
in multiple myeloma, mantle cell lymphoma, and follicular lymphoma:
a comparison with real-time PCR. J. Mol. Diagn. 17, 652–660. doi:
10.1016/j.jmoldx.2015.05.007
El-Gamal, M., Khan, M. A., and Oh, C. H. (2016). Advanced melanoma: a
progressive review of V600E-B-RAF kinase and drugs inhibiting it. Mini Rev.
Med. Chem. [Epub ahead of print].
Else, M., Dearden, C. E., and Catovsky, D. (2015). Long-term follow-up after purine
analogue therapy in hairy cell leukaemia. Best Pract. Res. Clin. Haematol. 28,
217–229. doi: 10.1002/cncr.23032
Ferrero, S., Monitillo, L., Mantoan, B., Barbero, D., Genuardi, E., Barbiero, S.,
et al. (2013). Rituximab-based pre-emptive treatment of molecular relapse
in follicular and mantle cell lymphoma. Ann. Hematol. 92, 1503–1511. doi:
10.1007/s00277-013-1797-y
Flockhart, R. J., Armstrong, J. L., Reynolds, N. J., and Lovat, P. E. (2009). NFAT
signalling is a novel target of oncogenic BRAF in metastatic melanoma. Br. J.
Cancer 101, 1448–1455. doi: 10.1038/sj.bjc.6605277
Frontiers in Pharmacology | www.frontiersin.org 9 October 2016 | Volume 7 | Article 363
fphar-07-00363 October 11, 2016 Time: 16:18 # 10
Guerrini et al. B-RAF Mutation and Digital PCR in HCL
Fontanelli, G., Baratè, C., Ciabatti, E., Guerrini, F., Grassi, S., Del Re, M., et al.
(2015). Real-time PCR and droplet digital PCR: two techniques for detection of
the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative
neoplasms. Int. J. Lab. Hematol. 37, 766–773. doi: 10.1111/ijlh.12404
Galimberti, S., Brizzi, F., Mameli, M., and Petrini, M. (1999). An advantageous
method to evaluate IgH rearrangement and its role in minimal residual disease
detection. Leuk. Res. 23, 921–929. doi: 10.1016/S0145-2126(99)00110-1 PMID:
10573138
Galimberti, S., Luminari, S., Ciabatti, E., Grassi, S., Guerrini, F., Dondi, A., et al.
(2014). Minimal residual disease after conventional treatment significantly
impacts on progression-free survival of patients with follicular lymphoma:
the FIL FOLL05 trial. Clin. Cancer Res. 20, 6398–6405. doi: 10.1158/1078-
0432.CCR-14-0407
Getta, B. M., Park, J. H., and Tallman, M. S. (2015). Hairy cell leukemia:
past, present and future. Best Pract. Res. Clin. Haematol. 28, 269–272. doi:
10.1016/j.beha.2015.10.015
Grimaldi, A. M., Simeone, E., Festino, L., Vanella, V., Palla, M., and Ascierto, P. A.
(2015). Novel mechanisms and therapeutic approaches in melanoma: targeting
the MAPK pathway. Discov. Med. 19, 455–461. PMID: 26175403
Jiang, L., Chu, H., and Zheng, H. (2016). B-Raf mutation and papillary thyroid
carcinoma patients. Oncol. Lett. 11, 2699–2705. doi: 10.3892/ol.2016.4298
Kamiyama, T., Aoki, N., and Yuasa, Y. (1993). B-raf oncogene: activation by
rearrangements and assignment to human chromosome 7. Jpn. J. Cancer Res.
84, 250–256. doi: 10.1111/j.1349-7006.1993.tb02864.x PMID: 8098025
Kreitman, R. J. (2013). Hairy cell leukemia-new genes, new targets. Curr. Hematol.
Malig. Rep. 8, 184–195. doi: 10.1007/s11899-013-0167-0
Luminari, S., Galimberti, S., Versari, A., Biasoli, I., Anastasia, A., Rusconi, C., et al.
(2016). Positron emission tomography response and minimal residual disease
impact on progression-free survival in patients with follicular lymphoma.
A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.
Haematologica 101, e66–e68. doi: 10.3324/haematol.2015.132811
Lyons, J. F., Wilhelm, S., Hibner, B., and Bollag, G. (2001). Discovery of a novel Raf
kinase inhibitor. Endocr. Relat. Cancer 8, 219–225. doi: 10.1677/erc.0.0080219
PMID: 11566613
Mason, E. F., Brown, R. D., Szeto, D. P., Gibson, C. J., Jia, Y., Garcia,
E. P., et al. (2016). Detection of activating MAP2K1 mutations in atypical
hairy cell leukemia and hairy cell leukemia variant. Leuk. Lymphoma doi:
10.1080/10428194.2016.1185786 [Epub ahead of print].
Miranda, R. N., Cousar, J. B., Hammer, R. D., Collins, R. D., and Vnencak-
Jones, C. L. (1999). Somatic mutation analysis of IgH variable regions reveals
that tumor cells of most parafollicular (monocytoid) B-cell lymphoma, splenic
marginal zone B-cell lymphoma, and some hairy cell leukemia are composed
of memory B lymphocytes. Hum. Pathol. 30, 306–312. doi: 10.1016/S0046-
8177(99)90010-2 PMID: 10088550
Mori, S., Vagge, E., le Coutre, P., Abruzzese, E., Martino, B., Pungolino, E., et al.
(2015). Age and dPCR can predict relapse in CML patients who discontinued
imatinib: the ISAV study. Am. J. Hematol. 90, 910–914. doi: 10.1002/ajh.24120
Ommen, H. B. (2016). Monitoring minimal residual disease in acute myeloid
leukaemia: a review of the current evolving strategies. Ther. Adv. Hematol. 7,
3–16. doi: 10.1177/2040620715614529
Pakneshan, S., Salajegheh, A., Smith, R. A., and Lam, A. K. (2013).
Clinicopathological relevance of BRAF mutations in human cancer. Pathology
45, 346–356. doi: 10.1097/PAT.0b013e328360b61d
Pott, C., Hoster, E., Delfau-Larue, M. H., Beldjord, K., Böttcher, S., Asnafi, V., et al.
(2010). Molecular remission is an independent predictor of clinical outcome in
patients with mantle cell lymphoma after combined immunochemotherapy: a
European MCL intergroup study. Blood 115, 3215–3223. doi: 10.1182/blood-
2009-06-230250
Ravandi, F. (2015). Chemoimmunotherapy for hairy cell leukemia. Best Pract. Res.
Clin. Haematol. 28, 230–235. doi: 10.1016/j.beha.2015.09.005
Salomon-Nguyen, F., Valensi, F., Troussard, X., and Flandrin, G. (1996). The value
of the monoclonal antibody, DBA44, in the diagnosis of B-lymphoid disorders.
Leuk. Res. 20, 909–913. PMID: 9009248
Sausville, J. E., Salloum, R. G., Sorbara, L., Kingma, D. W., Raffeld, M., Kreitman,
R. J., et al. (2003). Minimal residual disease detection in hairy cell leukemia.
Comparison of flow cytometric immunophenotyping with clonal analysis using
consensus primer polymerase chain reaction for the heavy chain gene. Am. J.
Clin. Pathol. 119, 213–217. doi: 10.1309/G629-9513-NGLC-UB1K
Schnittger, S., Bacher, U., Haferlach, T., Wendland, N., Ulke, M., Dicker, F., et al.
(2012). Development and validation of a real-time quantification assay to
detect and monitor BRAFV600E mutations in hairy cell leukemia. Blood 119,
3151–3154. doi: 10.1182/blood-2011-10-383323
Tallman, M. S. (2011). Implications of minimal residual disease in
hairy cell leukemia after cladribine using immunohistochemistry
and immunophenotyping. Leuk. Lymphoma 52(Suppl. 2), 65–68. doi:
10.3109/10428194.2011.566393
Tiacci, E., Trifonov, V., Schiavoni, G., Holmes, A., Kern, W., Martelli, M. P., et al.
(2011). BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305–2315.
doi: 10.1056/NEJMoa1014209
Tie, J., and Desai, J. (2015). Targeting BRAF mutant metastatic colorectal cancer:
clinical implications and emerging therapeutic strategies. Target. Oncol. 10,
179–188. doi: 10.1007/s11523-014-0330-0
van der Velden, V. H., Hochhaus, A., Cazzaniga, G., Szczepanski, T., Gabert, J., and
van Dongen, J. J. (2003). Detection of minimal residual disease in hematologic
malignancies by real-time quantitative PCR: principles, approaches,
and laboratory aspects. Leukemia 17, 1013–1034. doi: 10.1038/sj.leu.
2402922
Vogelstein, B., and Kinzler, K. W. (1999). Digital PCR. Proc. Natl. Acad. Sci. U.S.A.
96, 9236–9241. doi: 10.1073/pnas.96.16.9236 PMID: 10430926
Zagaria, A., Anelli, L., Coccaro, N., Tota, G., Casieri, P., Cellamare, A., et al. (2015).
BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and
molecular monitoring by droplet digital PCR. Virchows Arch. 467, 357–363. doi:
10.1007/s00428-015-1802-z
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Guerrini, Paolicchi, Ghio, Ciabatti, Grassi, Salehzadeh, Ercolano,
Metelli, Del Re, Iovino, Petrini, Carulli, Cecconi, Rousseau, Cervetti and Galimberti.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Pharmacology | www.frontiersin.org 10 October 2016 | Volume 7 | Article 363
